Knowledge centerChange control

Research Governance

When Should an Analysis Change Require Formal Approval?

A proportionate amendment pathway distinguishes routine implementation details from changes that alter the scientific question, bias risk, or interpretation.

Dr. Andrie Udal, PhD, MSHDSHealthcare Data Science Lead, ProWritePublished 27 July 2026Updated 27 July 2026
ProWrite editorial framework: make every critical decision explicit, reviewable, and traceable to the research record.

An analysis plan should be stable enough to protect the study from result-driven choices and flexible enough to respond to real data problems. Without change control, teams usually fall into one of two failures: they follow a broken method because it was written down, or they change the method silently and present the result as prespecified.

The solution is a proportionate analysis amendment pathway. Formal approval should be triggered by the consequence of the change, its timing, and the information available to the people proposing it—not merely by whether a line of code changed.

01Classify changes by scientific consequence

Low-consequence implementation details may include correcting a typographic error that does not change executable logic, clarifying a label, or optimizing code while reproducing the same output. These still belong in version control, but may not need committee review.

Moderate changes affect execution or presentation without intentionally changing the primary scientific question. Examples include replacing a model that fails to converge, correcting a derivation discovered during blinded review, or adding a sensitivity analysis after a documented assumption concern. They require a dated rationale, impact assessment, review by the statistical lead, and notification to the principal investigator.

High-consequence changes alter the estimand, primary outcome, analysis population, treatment contrast, covariate strategy, missing-data assumption, multiplicity control, subgroup claim, decision threshold, or interpretation of the main result. They should require formal multidisciplinary approval and, when relevant, alignment with protocol, registry, ethics, funder, or regulatory processes.

02Timing changes the risk

A change made before outcome data are available is not equivalent to the same change made after unblinding. The amendment record should state which data were accessible, to whom, and whether treatment labels or outcome patterns had been seen. This does not automatically invalidate a late change; it changes how independently the rationale can be judged and how the analysis must be labeled.

Whenever possible, use personnel who remain blinded to comparative results to assess data quality and feasibility issues. If unblinded information is essential, restrict access, document it, and involve an independent reviewer. The purpose is not to create a ceremonial signature. It is to prevent a preferred result from becoming the invisible reason for a methodological decision.

03Require a complete amendment record

Every material amendment should contain:

  1. the original specification and proposed replacement;
  2. the scientific or technical reason;
  3. date and data-access state;
  4. affected objectives, variables, outputs, and study documents;
  5. expected effect on bias, type I error, estimation, and interpretation;
  6. alternatives considered;
  7. decision, approvers, and implementation owner; and
  8. the reporting language that will disclose the change.

SPIRIT 2025 includes plans for communicating important protocol modifications, and the broader protocol-to-reporting framework expects consistency among the protocol, statistical analysis plan, registry, and manuscript. A change record is the bridge that explains legitimate differences across those artifacts.

04Verify the implementation separately

Approval of the concept does not prove that code implements it correctly. Link the approved amendment to a versioned code change and regenerated outputs. A second person should review high-consequence logic or independently reproduce critical results. The audit trail should show which dataset and software environment produced the revised analysis.

MHRA data-integrity guidance emphasizes traceability of processing parameters and reconstruction of repeated processing. Although institutional studies differ in regulatory context, the scientific principle is broadly useful: analysts should not be able to try progressive parameter changes and leave only the most desirable output visible.

05Report the change honestly

The final publication should identify the prespecified analysis, material amendments, timing, rationale, and any exploratory work. If the change was prompted by observed results, say so. If it changes the claim from confirmatory to exploratory, adjust the language rather than attempting to recover certainty with approval after the fact.

Research leaders can begin by creating three change tiers and naming the approver for each. Then test the pathway with one realistic case: a primary model fails an assumption check after unblinding. If the organization cannot say who decides, what evidence is retained, and how the manuscript will disclose it, its analysis governance is incomplete.

Set turnaround expectations as well. A pathway that takes weeks for every clarification encourages teams to bypass it. Rapid triage, proportionate reviewers, and an emergency route for safety-related changes make formal control usable under real research deadlines.

References

  1. SPIRIT 2025 Statementprotocol content, statistical analysis plans, and communication of important modifications. Accessed 27 July 2026.
  2. SPIRIT 2025 Explanation and Elaborationimplementation guidance and consistency among study documents. Accessed 27 July 2026.
  3. Gamble C, et al. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA. 2017SAP content, timing, and versioning. Accessed 27 July 2026.
  4. MHRA Guidance on GxP Data Integritytraceability, audit trails, data processing, and retained records. Accessed 27 July 2026.

This article is educational and intended for research purposes. It does not provide individual medical advice, diagnosis, or treatment. No patient data were used.